Participants (IMI): Gordana Pehnec, Marko Gerić, Ivana Jakovljević, Silvije Davila, Iva Šimić, Mirta Milić, Vilena Kašuba, Katarina Matković, Ivana Vrhovac Madunić, Dean Karaica, Maja Nikolić, Luka Kazensky, Vedran Micek, Davorka Breljak, Tajana Horvat i Marija Jelena Lovrić
Programme: HORIZON
Call: HORIZON-HLTH-2021-ENVHLTH-02
Duration: 01.12.2022. – 30.11.2026.
Abstract: Indoor air pollution, an emerging threat recognized by European society, is claiming millions of lives annually. In the heat of current COVID-19 pandemic, elevated exposure to indoor air pollutants due to increased time spent indoors further faces a significant increase in negative effect on both physical and mental health and well-being not only in Europe, but also worldwide. When it comes to indoor air quality itself, serious knowledge gaps remain in understanding complex nature of indoor-outdoor pollution relationships, pollution sources and exposure pathways, health effects of emerging pollutants, ventilation of indoor spaces on wide spatial and long temporal scales. This is mainly because air quality monitoring in European Union (EU) is primarily focused on outdoor air quality, which paradoxically is a result of regulatory target compliances, which is lacking for indoor environments. To increase the resilience of EU for emerging threats of indoor air pollution and to promote living and working in healthy environments, project EDIAQI aims at conducting characterization of sources and routes of exposure and dispersion of chemical, biological, and emerging indoor air pollution in multiple cities in EU. Quantification of the main properties of pollutants and processes that governs its fate in indoor environments will be investigated on two levels: a) the-state-of-the-art, small-scale, high-intensity scientific focus measurement campaigns; and b) long-term, large-scale monitoring of target indoor air pollutants. The chosen project strategy for developing, characterization, and deployment of cost-effective/user-friendly monitoring solutions, together with the-state-of-the-art scientific instrumentation will allow to create new knowledge on sources, routes of exposure, and body burdens of indoor multipollutant.
IMI Participants: Mirta Milić, Marko Gerić, Goran Gajski
Programme: Erasmus+
Action Type: KA220-HED – Cooperation partnerships in higher education
Field: Higher Education
Duration: 31.1.2022. – 31.1.2025.
Objectives: The Erasmus ToxLearn4EU project was built by a consortium of 7 HEIs and 3 research centres and laboratory. It aims to modernize of Toxicology and Ecotoxicology teaching in Europe and has several objectives and target audiences:
develop and use innovative and free educational resources interactive courses, online PBL) in order to develop high quality digital education
provide innovative content on current hot topics in the field of Toxicology/Ecotoxicology to fit with recent evolution of European Policy (Action Plan: ‘Towards Zero Pollution’) and with job market needs
stimulate interest of students for those fields and limit school dropout by putting students back at the centre of teaching through the use of active pedagogies adapted to digital practice to recreate interactions between students, between students and teachers, and by stimulating their motivation through playful approaches.
The project meets the needs of:
students by stimulating their interest and limiting school dropout, putting them back at the centre of teaching through the use of active pedagogies adapted to digital practice to recreate interactions between students, between students and teachers, and by stimulating their motivation through playful approaches.
teachers by proposing stimulating online courses which can be integrated in their own courses, or by motivating them to design and create their own new innovative courses.
partners by modernizing part of their curricula.
stakeholders of toxicology and ecotoxicology by developing student and lifelong learner competencies adapted to job market and up-to-date to recent changes at the European Level (Green Deal)
European Commission by modifying curricula and developing courses adapted to the Green Deal. This will contribute to reach the ambitious objectives of EU Action Plan Towards Zero Pollution.
Hrvatsko-njemački znanstvenoistraživački projekt financiran od strane Ministarstva znanosti i obrazovanja Republike Hrvatske i Njemačke službe za akademsku razmjenu (DAAD)
Voditelji projekta:
Ivana Vrhovac Madunić (hrvatski voditelj), IMI
Mladen V. Tzvetkov (njemački voditelj), University of Medicine, Greifswald
Suradnici na projektu: Maja Katalinić, Josip Madunić, Zrinka Kovarik, Antonio Zandona, Tena Čadež, Marleen Meyer, Sarah Rőmer
Suradnici na projektu: Maja Katalinić, Josip Madunić, Dean Karaica, Antonio Zandona, Ana-Marija Lulić
Zaklada Hrvatske akademije znanosti i umjetnosti
Trajanje: 2021. –2022.
Sažetak
Cilj ovog projekta je odrediti da li novosintetizirani oksimski spojevi sprječavaju unos glukoze i samim time rast ljudskih stanica raka prostate te se kao takvi mogu razmatrati kandidatima za antitumorske lijekove. Većina novosintetiziranih oksima koja ćemo ispitati ili su konstantno pozitivno nabijeni kvartarni amini, ili sadrže amino skupine koje bi mogle biti snažno protonirane u fiziološkim uvjetima.
Sažetak: The network aims at fueling urgently needed collaborations in the field of correlated multimodal imaging (CMI), promoting and disseminating its benefits through showcase pipelines, and paving the way for its technological advancement and implementation as a versatile tool in biological and preclinical research. CMI combines two or more imaging modalities to gather information about the same specimen. It creates a composite view of the sample with multidimensional information about its macro-, meso- and microscopic structure, dynamics, function and chemical composition. Since no single imaging technique can reveal all these details, CMI is the only way to understand biomedical processes and diseases mechanistically and holistically. CMI relies on the joint multidisciplinary expertise from biologists, physicists, chemists, clinicians and computer scientists, and depends on coordinated activities and knowledge transfer between academia and industry, and instrument developers and users. Due to its inherently multidisciplinary and cross-functional nature, an interdisciplinary network such as this Action is indispensable for the success of CMI. Nevertheless, there is currently no European network in the field. Existing scattered efforts focus on correlated light and electron microscopy or (pre)clinical hybrid imaging. This Action will consolidate these efforts, establish commonly-accepted protocols and quality standards for existing CMI approaches, identify and showcase novel CMI pipelines, bridge the gap between preclinical and biological imaging, and foster correlation software through networking, workshops and open databases. The network will raise awareness for CMI, train researchers in multimodal approaches, and work towards a scientific mindset that is enthusiastic about interdisciplinary imaging approaches in life sciences.
J. Kesić, M. Popsavin, G. Benedeković, V. Kojić, A. Bosak, A. Matošević, P. Farkaš, R. Madelová, V. Popsavin, I. Kovačević. Synthesis and biological evaluation of natural cleistanolate, its enantiomer and analogues. European Journal of Medicinal Chemistry, 2025,287,117326. doi: 10.1016/j.ejmech.2025.117326
K. Komatović, A. Matošević, M. Zlatović, D. Sladić, A. Bosak, D. Opsenica. Hybrids of 4-aminoquinolines and adamantane as inhibitors of AChE. Journal of the Serbian Chemical Society. 2025, prihvaćen za objavljivanje, doi:10.2298/JSC250131014K
M. Bartolić, A. Bosak. Overview of BACE1 structure and effect of genetic polymorphisms and protein isoforms on enzyme activity. Periodicum biologorum. 2024, prihvaćen za objavljivanje. doi:10.18054/pb.v126i3-4.33903.
M. Bartolić, A. Matošević, N. Maraković, V. Bušić, S. Roca, D. Vikić-Topić, A. Sabljić, A. Bosak, D. Gašo-Sokač. Evaluation of hydrazone and N-acylhydrazone derivatives of vitamin B6 and pyridine-4-carbaldehyde as potential drugs against Alzheimer’s disease. Journal of Enzyme Inhibition and Medicinal Chemistry.2024,39(1). doi: 10.1080/14756366.2024.2431832
A. Matošević, D. Opsenica, M. Bartolić, N. Maraković, A. Stoilković, K. Komatović, A. Zandona, S. Žunec, A. Bosak. Derivatives of amodiaquine as potent human cholinesterases inhibitors: Implication for treatment of Alzheimer’s disease. Molecules. 2024,29(2),5357. doi: 10.3390/molecules29225357
A. Matošević, M. Bartolić, N. Maraković, A. Zandona, R. Petrić, D.M. Opsenica, A. Bosak, Synthesis and biological evaluation of novel aminoquinolines with an n-octyl linker: Impact of halogen substituents on C(7) or a terminal amino group on anticholinesterase and BACE1 activity. Bioorganic & Medicinal Chemistry Letters2024, 112, 129928. doi: 10.1016/j.bmcl.2024.129928
A. Matošević, D.M. Opsenica, M. Spasić, N. Maraković, A. Zandona, S. Žunec, M. Bartolić, Z. Kovarik, A. Bosak, Evaluation of 4-aminoquinoline derivatives with an n-octylamino spacer as potential multi-targeting ligands for the treatment of Alzheimer’s disease, Chemico-biological Interactions2023, 382, 110620. doi: 10.1016/j.cbi.2023.110620
A. Matošević, A Knežević, A. Zandona, N. Maraković, Z. Kovarik, A. Bosak, Design, synthesis and biological evaluation of biscarbamates as potential selective butyrylcholinesterase inhibitors for the treatment of Alzheimer’s disease, Pharmaceuticals2022, 15, 1220. doi:10.3390/ph15101220 (IF (2021) = 5,21; Q1)
K. Komatović, A. Matošević, N. Terzić-Jovanović, S. Žunec, S. Šegan, M. Zlatović, N. Maraković, A. Bosak, D. Opsenica, 4-aminoquinoline-based adamantanes as potential anticholinesterase agents in symptomatic treatment of Alzheimer’s disease. Pharmaceutics 2022, 14, 1305. doi:10.3390/pharmaceutics14061305 (IF= 6,52 (2021); Q1)
A. Bosak. Development of bioactive molecules for neurodegenerative disease treatment. Mini-symposium: Multidisciplinarity in drug development, Zagreb, 12.2.2025. (sažetak)
M. Bartolić, A. Bosak. Multi-target approach to the treatment of Alzheimer’s disease: revival of amyloid theory. Mini-symposium: Multidisciplinarity in drug development, Zagreb, 12.2.2025. (sažetak)
A. Matošević, Development of carbamate-based compounds as potential cholinesterase inhibitors for the treatment of Alzheimer`s disease. Mini-symposium: Multidisciplinarity in drug development, Zagreb, 12.2.2025. (sažetak)
K. Komatović, N. Terzić-Jovanović, M. Zlatović, A. Matošević, N. Maraković, D. Opsenica, A. Bosak. Adamantane derivatives of 4-aminoquinoline as inhibitors of hAChE and hBChE: design and synthesis. Mini-symposium: Multidisciplinarity in drug development, Zagreb, 12.2.2025. (sažetak)
A. Zandona. Cytotoxicity of aminoquinoline and carbamate cholinesterase inhibitors. Mini-symposium: Multidisciplinarity in drug development, Zagreb, 12.2.2025. (sažetak)
S. Žunec. Antioxidant testing in development of multifunctional drug candidates for neurodegenerative diseases. Mini-symposium: Multidisciplinarity in drug development, Zagreb, 12.2.2025. (sažetak)
S. Šegan, M. Zlatović, N. Maraković, A. Bosak, D. Opsenica. QSAR insights in 4-aminoquinoline derivatives as AChE and BChE inhibitors. Mini-symposium: Multidisciplinarity in drug development, Zagreb, 12.2.2025. (sažetak)
M. Bartolić, D. Gašo Sokač, V. Bušić, A. Ramić, I. Primožič, A. Bosak. Comparison of structurally different ligands’ ability to prevent amyloid formation in Alzheimer’s disease. FEBS3+ Meeting Exploring Molecular Frontiers. Pula, 25.-28.9.2024.
A. Bosak, A. Matošević, I. Primožič. Carbamates – A privileged pharmacophore in the design of potent cholinesterase inhibitors for treating alzheimer’s disease. FEBS3+ Meeting Exploring Molecular Frontiers. Pula, 25.-28.9.2024.
A. Matošević, N. Maraković, Z. Kovarik, A. Bosak. BChE polymorphism effect on the efficiency of 5-(2-amino-1-hydroxyethyl) phenol carbamates as potential new drugs for advanced Alzheimer`s disease treatment. FEBS3+ Meeting Exploring Molecular Frontiers. Pula, 25.-28.9.2024.
A. Matošević, A. Bosak. Synthesis and biological evaluation of carbamate derivatives of 3-(2-amino-1-hydroxyethyl) phenol as potential drugs for the treatment of Alzheimer`s disease. 11th EFMC Young Medicinal Chemists’ Symposium & The XXVIII EFMC International Symposium on Medicinal Chemistry, Rim, Italija, 1.-.9.2024.
M. Bartolić, A. Bosak. Prospect for development of Alzheimer’s disease drugs based on 4-aminoquinoline scaffold, 11th EFMC Young Medicinal Chemists’ Symposium & The XXVIII EFMC International Symposium on Medicinal Chemistry, Rim, Italija, 1.-.9.2024.
M. Bartolić, D. Gašo-Sokač, V. Bušić, A. Ramić, I. Primožič, A Bosak, Amyloid-targeting approach for treatment of Alzheimer’s disease: biological evaluation of different structural scaffolds. 8th Faculty of Science PhD Student Symposium, Zagreb, 2024.
M. Bartolić, A. Bosak. Small Molecules, Big Dreams: In Search of Multi-Target Directed Ligands for the Treatment of Alzheimer’s Disease. 9th Conference of Young Chemists of Serbia, Novi Sad, Srbija, 2023.
M. Bartolić, P. Šušak, M. Arežina, M. Laučan, A. Ramić, T. Hrenar, I. Primožič, A. Bosak. Quinuclidinium based O-alkyl oximes as potential anticholinesterase agents in symptomatic treatment of Alzheimer’s disease. 10th EFMC Young Medicinal Chemists’ Symposium & IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry. Zagreb, 2023.
I. Novaković, A. Matošević, V. Milovanović, M. Bartolić, D. Opsenica, D. Sladić, A. Bosak. 1,4-benzoquinones as potent agents for Alzheimer`s disease treatment. IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry. Zagreb, 2023.
A. Bosak, A. Matošević, D.M. Opsenica, N. Maraković, A. Zandona, S. Žunec, M. Bartolić, S. Šegan. N-octylamino derivatives of 4-aminoquinoline as possible multifuctional agents for Alzheimer`s disease treatment. IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry. Zagreb, 2023.
A. Matošević, A. Bosak, A. Zandona, N. Maraković. Carbamates as potential new drugs in the treatment of Alzheimer`s disease. IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry &10th EFMC Young Medicinal Chemist`s Symposium. Zagreb, 2023.
M. Bartolić, A. Matošević, M. Spasić, D. Opsenica, A. Bosak. Evaluation of 4-aminoquinolines as potential MTDL ligands for the treatment of Alzheimer`s disease, Joint IUBMB/FEBS Advanced Lecture Course “Molecular targets for anti-aging interventions” Spetses Island, Grčka, 26.9.-1.10.2022.
A. Matošević, A. Knežević, A. Zandona, N. Maraković, Z. Kovarik, A. Bosak. Design, synthesis and biological evaluation of biscarbamates as potentialselective butyrylcholinesterase inhibitors for the treatment of Alzheimer`s disease, Joint IUBMB/FEBS Advanced Lecture Course “Molecular targets for anti-aging interventions”, Spetses Island, Grčka, 26.9.-1.10.2022.
K. Komatović, A. Matošević, M. Spasić, N. Maraković, A. Bosak, D. Opsenica. Synthesis and biological evaluation of 4-amino-7- chloroquinolines as novel reversible inhibitors of human cholinesterases, Congress of the Croatian Society of Biochemistry and Molecular Biology HDBMB22: From Science to Knowledge, Brela, Hrvatska 28.9.-1.10.2022.
M. Bartolić, A. Matošević, V. Bušić, D. Gašo Sokač, A. Bosak. Evaluation of hydrazone-based compounds as potential drugs for treatment of Alzheimer’s disease, European School of Medicinal Chemistry- 41st Advanced Course of Medicinal Chemistry and “E. Duranti” Seminar for PhD Students, Urbino, Italija, 3.-7.7. 2022.
A. Matošević, A. Knežević, N. Maraković, Z. Kovarik, A. Bosak. Design, synthesis and biological evaluation of cyclic biscarbamates as selective butyrylcholinesterase inhibitors in the treatment of Alzheimer`s disease, European School of Medicinal Chemistry- 41st Advanced Course of Medicinal Chemistry and “E. Duranti” Seminar for PhD Students, Urbino, Italija, 3.-7.7. 2022.
M. Bartolić, A. Matošević, V. Bušić, D. Gašo-Sokač, A. Bosak. Hydrazone-based compounds evaluated as inhibitors of human cholinesterases, 17th International Symposium on Cholinergic Mechanisms (ISCM2022), 17th International Symposium on Cholinergic Mechanisms (ISCM2022), Dubrovnik, 8.-12.5.2022.
A. Matošević, A. Knežević, A. Zandona, N. Maraković, M. Katalinić, Z. Kovarik, A. Bosak. Synthesis and biological evaluation of heterocyclic meta-biscarbamates, 17th International Symposium on Cholinergic Mechanisms (ISCM2022), Dubrovnik, 2022.
D. Opsenica, A. Bosak, A. Matošević, K. Komatović, N. Maraković. 4-aminoquinolines, a privileged pharmacophore- from antimalarials to inhibition of cholinesterase. Book of Abstracts of the 27th Croatian Meeting of Chemists and Chemical Engineers (27HSKIKI). Veli Lošinj, Hrvatska. 5.-8.10.2021. (sažetak)
A. Matošević, A. Bosak. Application of NMR for monitoring the synthetic route and characterization of bisacrbamates. The Adriatic NMR Conference 2021. Primošten, Hrvatska. 13.-15.9.2021.; str. 46. (poster, sažetak)
K. Komatović, A. Matošević, N. Terzić- Jovanović, A. Bosak, D. Opsenica. Adamantane based derivatives as reversible inhibitors of human AChE and BChE. FEBS Open Bio 11 (Suppl. 1); 45th FEBS Congress, Molecules of Life: Towards New Horizons. Ljubljana, Slovenija. 3.-8. 7. 2021.; str. 213. (poster)
A. Bosak, A. Matošević, A. Zandona, G. Šinko, K. Komatović, D. Opsenica. New 4-aminoquinoline-based cholinesterase inhibitors. FEBS Open Bio (Suppl. 1); 45th FEBS Congress, Molecules of Life: Towards New Horizons. Ljubljana, Slovenija. 3.–8. 7. 2021.; str. 310.-311. (poster, sažetak)
A. Matošević, A. Knežević, A. Bosak. Heterocyclic carbamates as potential drugs for the treatment of the neurodegenrative diseases. The 29th European Colloquium on Heterocyclic Chemistry. Rouen, Francuska, 26-28. 4. 2021.; str. 143. (poster, sažetak)
A. Matošević, A. Bosak. Design, synthesis and biological evaluation of compounds as active drugs in the central and peripheral nervous system. 5. Simpozij studenata doktorskih studija PMF-a, Zagreb, Hrvatska, 24-25. 4. 2021.; str. 146. (poster, sažetak)
M. Bartolić, D. Gašo Sokač, V. Bušić, A. Ramić, I. Primožič, A. Bosak. Comparison of structurally different ligands’ ability to prevent amyloid formation in Alzheimer’s disease. FEBS3+ Meeting Exploring Molecular Frontiers. Pula, 2024.
A. Bosak, A. Matošević, I. Primožič. Carbamates – A privileged pharmacophore in the design of potent cholinesterase inhibitors for treating alzheimer’s disease. FEBS3+ Meeting Exploring Molecular Frontiers. Pula, 2024.
A. Matošević, N. Maraković, Z. Kovarik, A. Bosak. BChE polymorphism effect on the efficiency of 5-(2-amino-1-hydroxyethyl) phenol carbamates as potential new drugs for advanced Alzheimer`s disease treatment. FEBS3+ Meeting Exploring Molecular Frontiers. Pula, 2024.
A. Matošević, A. Bosak. Synthesis and biological evaluation of carbamate derivatives of 3-(2-amino-1-hydroxyethyl) phenol as potential drugs for the treatment of Alzheimer`s disease. 11th EFMC Young Medicinal Chemists’ Symposium & The XXVIII EFMC International Symposium on Medicinal Chemistry, Rim, Italija, 2024.
M. Bartolić, A. Bosak. Prospect for development of Alzheimer’s disease drugs based on 4-aminoquinoline scaffold. The XXVIII EFMC International Symposium on Medicinal Chemistry, Rim, Italija, 2024.
M. Bartolić, Alma Ramić, Tomica Hrenar, Ines Primožič, Anita Bosak. Quinuclidinium oximes as cholinesterases’ and amyloid formation inhibitors. EMBO Workshop: Molecular Neurobiology 2024, Heraklion, Grčka, 2024.
M. Bartolić, D. Gašo-Sokač, V. Bušić, A. Ramić, I. Primožič, A Bosak, Amyloid-targeting approach for treatment of Alzheimer’s disease: biological evaluation of different structural scaffolds. 8th Faculty of Science PhD Student Symposium, Zagreb, 2024.
M. Bartolić, A. Bosak. Small Molecules, Big Dreams: In Search of Multi-Target Directed Ligands for the Treatment of Alzheimer’s Disease. 9th Conference of Young Chemists of Serbia, Novi Sad, Srbija, 2023.
A. Matošević, A. Bosak. Design, synthesis and biological evaluation of carbamates as cholinesterases inhibitors in the treatment of Alzheimer`s disease. 9th Conference of Young Chemists of Serbia. Novi Sad, Srbija, 2023.
M. Bartolić, P. Šušak, M. Arežina, M. Laučan, A. Ramić, T. Hrenar, I. Primožič, A. Bosak. Quinuclidinium based O-alkyl oximes as potential anticholinesterase agents in symptomatic treatment of Alzheimer’s disease. 10th EFMC Young Medicinal Chemists’ Symposium & IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry. Zagreb, 2023.
I. Novaković, A. Matošević, V. Milovanović, M. Bartolić, D. Opsenica, D. Sladić, A. Bosak. 1,4-benzoquinones as potent agents for Alzheimer`s disease treatment. IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry. Zagreb, 2023.
A. Bosak, A. Matošević, D.M. Opsenica, N. Maraković, A. Zandona, S. Žunec, M. Bartolić, S. Šegan. N-octylamino derivatives of 4-aminoquinoline as possible multifuctional agents for Alzheimer`s disease treatment. IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry. Zagreb, 2023.
A. Matošević, A. Bosak, A. Zandona, N. Maraković. Carbamates as potential new drugs in the treatment of Alzheimer`s disease. IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry &10th EFMC Young Medicinal Chemist`s Symposium. Zagreb, 2023.
M. Bartolić, A. Matošević, M. Spasić, D. Opsenica, A. Bosak. Evaluation of 4-aminoquinolines as potential MTDL ligands for the treatment of Alzheimer`s disease, Joint IUBMB/FEBS Advanced Lecture Course “Molecular targets for anti-aging interventions” Spetses Island, Grčka, 2022.
A. Matošević, A. Knežević, A. Zandona, N. Maraković, Z. Kovarik, A. Bosak. Design, synthesis and biological evaluation of biscarbamates as potentialselective butyrylcholinesterase inhibitors for the treatment of Alzheimer`s disease, Joint IUBMB/FEBS Advanced Lecture Course “Molecular targets for anti-aging interventions”, Spetses Island, Grčka, 2022.
K. Komatović, A. Matošević, M. Spasić, N. Maraković, A. Bosak, D. Opsenica. Synthesis and biological evaluation of 4-amino-7- chloroquinolines as novel reversible inhibitors of human cholinesterases, Congress of the Croatian Society of Biochemistry and Molecular Biology HDBMB22: From Science to Knowledge, Brela, Hrvatska, 2022.
M. Bartolić, A. Matošević, V. Bušić, D. Gašo Sokač, A. Bosak. Evaluation of hydrazone-based compounds as potential drugs for treatment of Alzheimer’s disease, European School of Medicinal Chemistry- 41st Advanced Course of Medicinal Chemistry and “E. Duranti” Seminar for PhD Students, Urbino, Italija, 2022.
A. Matošević, A. Knežević, N. Maraković, Z. Kovarik, A. Bosak. Design, synthesis and biological evaluation of cyclic biscarbamates as selective butyrylcholinesterase inhibitors in the treatment of Alzheimer`s disease, European School of Medicinal Chemistry- 41st Advanced Course of Medicinal Chemistry and “E. Duranti” Seminar for PhD Students, Urbino, Italija, 2022.
M. Bartolić, A. Matošević, V. Bušić, D. Gašo-Sokač, A. Bosak. Hydrazone-based compounds evaluated as inhibitors of human cholinesterases, 17th International Symposium on Cholinergic Mechanisms (ISCM2022), 17th International Symposium on Cholinergic Mechanisms (ISCM2022), Dubrovnik, 2022.
A. Matošević, A. Knežević, A. Zandona, N. Maraković, M. Katalinić, Z. Kovarik, A. Bosak. Synthesis and biological evaluation of heterocyclic meta-biscarbamates, 17th International Symposium on Cholinergic Mechanisms (ISCM2022), Dubrovnik, 2022.
D. Opsenica, A. Bosak, A. Matošević, K. Komatović, N. Maraković. 4-aminoquinolines, a privileged pharmacophore- from antimalarials to inhibition of cholinesterase. Book of Abstracts of the 27th Croatian Meeting of Chemists and Chemical Engineers (27HSKIKI). Veli Lošinj, Hrvatska. 2021.
A. Matošević, A. Bosak. Application of NMR for monitoring the synthetic route and characterization of bisacrbamates. The Adriatic NMR Conference 2021. Primošten, Hrvatska. 2021.
K. Komatović, A. Matošević, N. Terzić- Jovanović, A. Bosak, D. Opsenica. Adamantane based derivatives as reversible inhibitors of human AChE and BChE. FEBS Open Bio 11 (Suppl. 1); 45th FEBS Congress, Molecules of Life: Towards New Horizons. Ljubljana, Slovenija. 2021.
A. Bosak, A. Matošević, A. Zandona, G. Šinko, K. Komatović, D. Opsenica. New 4-aminoquinoline-based cholinesterase inhibitors. FEBS Open Bio (Suppl. 1); 45th FEBS Congress, Molecules of Life: Towards New Horizons. Ljubljana, Slovenija. 2021.
A. Matošević, A. Knežević, A. Bosak. Heterocyclic carbamates as potential drugs for the treatment of the neurodegenrative diseases. The 29th European Colloquium on Heterocyclic Chemistry. Rouen, Francuska, 2021.
A. Matošević, A. Bosak. Design, synthesis and biological evaluation of compounds as active drugs in the central and peripheral nervous system. 5. Simpozij studenata doktorskih studija PMF-a, Zagreb, Hrvatska, 2021.
Novi projekti
A. Matošević. Potpora Zaklade Hrvatske akademije znanosti i umjetnosti za projekt „Sinteza i biološka evaluacija karbamata kao potencijalnih inhibitora kolinesteraza u tretmanu Alzheimerove bolesti“
Nagrade/priznanja/stipendije
M. Bartolić. Godišnja nagrada Hrvatskog kemijskog društva za mlade medicinske i farmaceutske kemičare za 2023.
M. Bartolić. EMBO Mol Neuro 2024 – travel grant za sudjelovanje na EMBO Workshop Molecular neurobiology, 2024, Heraklion, Grčka
A. Matošević. Stipendija European Federation for Medicinal Chemistry za sudjelovanje na XXVIII EFMC International Symposium on Medicinal Chemistry & EFMC-Young Medicinal Chemists’ Symposium, 2024, Rim, Italija
M. Bartolić. Stipendija Hrvatskog kemijskog društva za sudjelovanje na XXVIII EFMC International Symposium on Medicinal Chemistry, 2024, Rim, Italija
A. Matošević. Stipendija Hrvatskog društva za biokemiju i molekularnu biologiju za sudjelovanje na FEBS3+ Meeting: Exploring molecular Frontiers, 2024. Pula, Hrvatska
A. Matošević. Stipendija Hrvatskog kemijskog društva za sudjelovanje na Xth EFMC Young Chemist`s Symposium, 2023, Zagreb, Hrvatska
A. Matošević. FEBS Travel Grant za sudjelovanje na Joint IUBMB/FEBS Advanced Lecture Course Molecular Targets for Anti-aging Interventions, 2022, Spetses Island, Grčka
A. Matošević. The Young ISN Neurochemistry Award za sudjelovanje na 17th International Symposium on Cholinergic Mechanisms, 2022, Dubrovnik, Hrvatska
Organizacije događanja
Simpozij povodom završetka projekta 9343. Mini-symposium: Multidisciplinarity in drug development, Zagreb, 12.2.2025., Institut za medicinska istraživanjai medicinu rada. Organizatori: A. Bosak, A. Matošević i M. Bartolić
2024. Diplomski rad studentice Kemije na Prirodoslovno- matematičkom fakultetu u Zagrebu Petre Šušak “Inhibicija humanih kolinesteraza O-alkiloksimima”- mentorica dr. sc. A. Bosak, neposredna voditeljica M. Bartolić, mag. chem.
2023. Diplomski rad studentice Kemije na Prirodoslovno- matematičkom fakultetu u Zagrebu Aleksandrine Vodolšak “Sinteza i biološka evaluacija heterocikličkih karbamata kao inhibitora humanih kolinesterazaima”- mentorica dr. sc. A. Bosak, neposredna voditeljica dr. sc. A. Matošević
2023. Stručna praksa studentice Kemije na Prirodoslovno- matematičkom fakultetu u Zagrebu Petre Šušak“- mentorica dr. sc. A. Matošević
2021. Stručna praksa studentice Kemije na Prirodoslovno- matematičkom fakultetu u Zagrebu Aleksandrina Vodolšak “- mentorica dr. sc. A. Matošević
2021. Sudjelovanje u održavanju kolegija Praktikum biokemije studentima III. godine Prediplomskog studija Kemije na Prirodoslovno-matematičkom fakultetu u Zagrebu- dr. sc. A. Matošević
Popularizacija znanosti i projekta
A. Matošević. Predavanje “Dizajn, sinteza i evaluacija potencijalnih lijekova -primjer Alzheimerove bolesti”, Prirodoslovna škola Karlovac, Karlovac 14.4.2025.
A. Matošević. Dani otvorenih vrata IMI. Obilazak laboratorija uz demonstraciju rada,IMI, Zagreb, 22.11.2024. Učenici osnovnih i srednjih škola te studenti.
A. Matošević. Organska kemija na IMI-ju. Obilazak laboratorija uz demonstraciju rada, IMI, Zagreb, 14.11.2024. Maturanti Gimazije Daruvar
M. Bartolić, A. Matošević. Dan karijera PMF-a WISe – WorkIn’ Science, PMF, Zagreb, 5.11.2024.
M. Bartolić. Je li znanstveni rad težak? Radionica, IMI, Zagreb, 22.3.2024. Učenici 8. r.
M. Bartolić, A. Matošević; EU-OPENSCREEN Autumn training school 2023 on topics related to Chemical biology & Drug discovery, 20.-22.11.2023. (on-line)
M. Bartolić, A. Matošević; International training on cell culture cultivation and cell-assay performance, 1.-12.10.2023., Zagreb, Hrvatska
M. Bartolić, A. Bosak, A. Matošević; Shimadzu radionica “Nexera LC-40 with PDA detector- Theory, LabSolution software, maintenance, troubleshooting”, 15.-17.2.2023., Zagreb, Hrvatska
A. Bosak, A. Matošević; FDA Clinical Investigator Training Course, U. S. Food & Drug Administration, 7.-8.12.2022. (on-line)
M. Bartolić, A. Bosak, A. Matošević; 1st Workshop in Mass Spectrometry in Life Sciences, Prirodoslovno-matematički fakultet, Zagreb, 24.-26.11.2022.
M. Bartolić, A. Matošević; Uvod u molekulsko modeliranje, Institut “Ruđer Bošković”, Zagreb, 2.-6.12.2021.
M. Bartolić, Education workshop – Better skills for better jobs: excellent lab book for an excellent career, 11.-12.11.2021. (on-line)
A. Bosak; seminar Uvod u upravljanje projektima, Bicro Biocentar, Zagreb, 26. 10. 2021.
M. Bartolić, A. Matošević; Praktična radionica Tekućinska kromatografija i spektrometrija masa, BICRO BIOCentar d.o.o., Zagreb 12.-13.10.2021.
A. Matošević; SPICA Virtual Session The importance of Chromatography in the Development of Vaccines, 14.10.2021. (on-line)
A. Matošević; 2nd Symeres Precision Chemistry Conference on Tools for Molecular Recognition and Diagnostics, 12.-13.10.2021. (on-line)
A. Matošević; Reaxys webinar, Hrvatsko kemijsko društvo i Elsevier, 23.04.2021.
A. Matošević, webinar, Intact and peptide level characterization of nanobodies by high resolution HPLC-MS/MS, 12.2.2021.
Projekt u slikama…
A. Matošević (lijevo) i M. Bartolić (desno), Joint IUBMB/FEBS Advanced Lecture Course “Molecular targets for anti-aging interventions”, Spetses Island, Grčka, 2022.
A. Matošević (lijevo) i M. Bartolić (desno), European School of Medicinal Chemistry- 41st Advanced Course of Medicinal Chemistry and “E. Duranti” Seminar for PhD Students , Urbino, Italija, 2022.
A. Bosak, A.Matošević i M. Bartolić (s lijeva) 17th International Symposium on Cholinergic Mechanism, Dubrovnik
A. Matošević; 5. Simpozij studenata doktorskih studija PMF-a, Zagreb, Hrvatska, 2021.
Bez obzira što su poliaromatski ugljikovodici (PAU) i postojana organska zagađivala (engl. Persistent Organic Pollutants; POPs) intenzivno istraživani tijekom posljednjih nekoliko desetljeća, oni su i dalje s jednakim intenzitetom prisutni u znanstvenim istraživanjima širom svijeta s ciljem određivanja njihove raspodjele u okolišu i procjene utjecaja na ljudsko zdravlje. PAU su složena skupina onečišćujućih tvari koje nastaju nepotpunim izgaranjem organskog materijala. Mnoge zemlje širom svijeta, uključujući Hrvatsku, prate kvalitetu vanjskog zraka putem svojih mreža za praćenje, te se podaci o PAU u zraku koriste za mjere smanjenja emisija. POPs su spojevi čija su zajednička svojstva postojanost, bioakumulacija, otrovnost, i prijenos zračnim masama na velike udaljenosti. S ciljem prestanka ili smanjenja ispuštanja POPs-ova u okoliš, uvedena je Stockholmska konvencija o postojanim organskim zagađivalima. Konvencija je stupila na snagu 2004. god., a 2006. godine Sabor RH proglasio je Zakon o potvrđivanju Stockholmske konvencije o postojanim organskim onečišćujućim tvarima (NN – MU 11/2006). Između ostalog, Konvencijom je propisano pratiti postojeće razine u biotičkom i abiotičkom okolišu.
Na ovom projektu započeta je suradnja sa JU AQUATIKA, koja se nadovezuje na višegodišnju suradnju grupe istraživača iz Hrvatske (Odjel za zdravstvene studije Sveučilišta u Zadru i IMI, Zagreb) i iz Srbije (Institut za fiziku, Hemijski fakultet i Institut za nuklearne znanosti Vinča Univerziteta u Beogradu).
Suradnici:
IMI
Jedinica za biokemiju i organsku analitičku kemiju
Cilj je ovog projekta optimiranje uvjeta za ekstrakciju potpomognutu mikrovalovima (MAE) 7 kongenera polibromiranih difenil etera (PBDE) iz uzoraka ljudskog mlijeka odabirom pogodne smjese otapala i temperature, te vremena potrebnog za ekstrakciju. Poseban naglasak stavljen je na utjecaj predobrade uzorka ljudskog mlijeka na učinkovitost tehnike MAE. Radi se o prvoj primjeni tehnike MAE za ekstrakciju spojeva PBDE iz uzoraka ljudskog mlijeka u svijetu, a dobiveni rezultati dat će preliminarne podatke o masenim udjelima spojeva PBDE u mlijeku rodilja iz Hrvatske koji će omogućiti i procjenu izloženosti hrvatske populacije spojevima PBDE, a na temelju čega će se moći procijeniti potencijalni rizik za zdravlje ljudi.
